NVO
Novo Nordisk A/S (NYSE: NVO) had its price target lowered to $36 from $45 as BMO Capital lowered...
Article Summary
HOLD- Novo Nordisk A/S (NYSE: NVO) had its price target lowered to $36 from $45 as BMO Capital lowered expectations for Wegovy Pill revenue, citing concerns that first-quarter revenue may fall short of market expectations.
- The firm maintained a Market Perform rating, noting that meaningful revenue growth from the pill format likely requires expanded uptake of higher-dose offerings.
- Novo Nordisk ADR noted that capture rates improved to 60% from 50% during the quarter, with roughly 721,000 WegovY Pill prescriptions written in the first quarter of 2026 based on IQVIA data, translating to about 1.3 million total prescriptions.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 11.1% | 25% | 50.0 ptsMeets Minimum (11.1%) - Passes screener |
| EPS Growth Next 5Y ? | -0.3% | 25% | 0.0 ptsNegative (-0.3%) - Declining expectations |
| Target Price Upside ? | 23.1% | 20% | 70.0 ptsGood Upside (23.1%) - Target: $48.26 vs Current: $39.20 |
| Gross Margin % ? | 80.9% | 15% | 100.0 ptsExceptional (80.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -51.9% | 15% | 100.0 ptsDeep Discount (-51.9%) - Best entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVO
- Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
- It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
- The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
- The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles.
- It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
- Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.